bluebird bio, Inc. and Gritstone Oncology, Inc. announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy.  Gritstone Oncology will leverage its proprietary EDGE™ artificial intelligence platform to analyze specific tumor types to identify tumor-specific targets and natural T-cell receptors (TCRs) directed to those targets for use in bluebird bio’s established cell therapy platforms. bluebird bio will conduct all development, manu...